Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

    ... placement (ORadj=6.47, 95% CI: 2.37, 17.62) and red blood cell transfusion (ORadj=4.60, 95% CI: 2.29, 9.23) were associated with deep vein ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... more and longer haematological responses and increased red blood cell transfusion independence . Azacitidine prolonged overall survival versus ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... mimetic eltrombopag (Promacta) can improve blood counts. Twenty-five patients received eltrombopag at a dose of 50 mg, ... were clinically significant changes in blood counts or transfusion independence . Patients with a response continued to receive ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... Journal Title:  Blood Primary Author:  ... (66%) patients on treatment for over 12 months achieved transfusion independence on eculizumab. The mean transfusion requirement ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... of hematopoietic stem cells and progeny mature blood cells which are deficient in some surface proteins, including the two ... clinical benefit. Anti-complement treatment allowed transfusion independence in at least half of PNH patients receiving ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies

    ... gene, which impairs the membrane expression on affected blood cells of a number of proteins, including the complement regulators CD55 ... leading to hemoglobin stabilization and transfusion independence in more than half of the patients. However, recent ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

    ... to 20%. Oral and SC azacitidine decreased DNA methylation in blood, with maximum effect at day 15 of each cycle. Hematologic responses ... remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

    ... Transfusion dependency and iron overload are common among patients with ... myelodysplastic syndromes (MDS) treated with red blood cell (RBC) transfusions. Transfusion dependency is associated with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Myelodysplastic syndromes and the role of iron overload.

    ... in patients with MDS due to the long-term use of red blood cell transfusions in patients with symptomatic anemia . ... options for patients with MDS do not always reduce the transfusion burden, many patients will still need long-term transfusion ...

    Research Article last updated 07/20/2018 - 5:14pm.